Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 04:41 pm EST
Share
Interpace Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 8.19 million compared to USD 8.06 million a year ago. Net loss was USD 14.21 million compared to USD 3.56 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.32 a year ago. Diluted loss per share from continuing operations was USD 0.3 compared to USD 0.32 a year ago. Basic loss per share was USD 3.35 compared to USD 0.85 a year ago. Diluted loss per share was USD 3.35 compared to USD 0.85 a year ago.
For the nine months, sales was USD 23.51 million compared to USD 24.01 million a year ago. Net loss was USD 20.39 million compared to USD 11.21 million a year ago. Basic loss per share from continuing operations was USD 1.05 compared to USD 1.29 a year ago. Diluted loss per share from continuing operations was USD 1.05 compared to USD 1.29 a year ago. Basic loss per share was USD 4.82 compared to USD 2.72 a year ago. Diluted loss per share was USD 4.82 compared to USD 2.72 a year ago.
Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.